Home › Research › Biomarkers
Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management
Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M, Momota Y, Suzuki N et al.. Neurology, 2022-09-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and objectives Previous studies have evaluated the diagnostic effect of amyloid PET in selected research cohorts. However, these studies did not assess the clinical impact of the combination of amyloid and tau PETs. Our objective was to evaluate the association of the combination of 2 PETs with changes in diagnosis, treatment, and management in a memory clinic cohort. Methods All participants underwent amyloid [ 18 F]florbetaben PET and tau PET using [ 18 F]PI-2620 or [ 18 F]Florzolotau, which are potentially useful for the diagnosis of non-Alzheimer disease (AD) tauopathies. Dementia specialists determined a pre- and post-PET diagnosis that existed in both a clinical syndrome (cognitive normal [CN], mild cognitive impairment [MCI], and dementia) and suspected etiology, with a confidence level. In addition, the dementia specialists determined patient treatment in terms of ancillary investigations and management. Results Among 126 registered participants, 84.9% completed the study procedures and were included in the analysis (CN [n = 40], MCI [n = 25], AD [n = 20], and non-AD dementia [n = 22]). The etiologic diagnosis changed in 25.0% in the CN, 68.0% in the MCI, and 23.8% with dementia. Overall changes in management between pre- and post-PET occurred in 5.0% of CN, 52.0% of MCI, and 38.1% of dementia. Logistic regression analysis revealed that tau PET has stronger associations with change management than amyloid PET in all participants and dementia groups. Discussion The combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia, and the second-generation tau PET has a strong impact on the changes in diagnosis and management in memory clinics. Classification of evidence This study provides Class I evidence that the combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia.
What this study adds
Evidence grade: Moderate
The record lists 40 participants. In 126 memory clinic participants, combining amyloid and tau PET scans changed the suspected cause of symptoms in many patients and changed management for about half of those with mild cognitive impairment. Reported effect size: 84.9%; 25.0%; 68.0%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shimohama, S., Tezuka, T., Takahata, K., Bun, S., Tabuchi, H., Seki, M., et al. (2023). Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management. Neurology. https://doi.org/10.1212/wnl.0000000000201389
Vancouver
Shimohama S, Tezuka T, Takahata K, Bun S, Tabuchi H, Seki M, et al. Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management. Neurology. 2023. doi:10.1212/wnl.0000000000201389. PMID: 36175151.
BibTeX
@article{shimohama2023-36175151,
author = {Shimohama, S. and Tezuka, T. and Takahata, K. and Bun, S. and Tabuchi, H. and Seki, M. and Momota, Y. and Suzuki, N. and others},
title = {{Impact of Amyloid and Tau PET on Changes in Diagnosis and Patient Management}},
journal = {Neurology},
year = {2023},
doi = {10.1212/wnl.0000000000201389},
pmid = {36175151},
url = {https://doi.org/10.1212/wnl.0000000000201389}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Among 126 registered participants, 84.9% completed the study procedures and were included in the analysis (CN [n = 40], MCI [n = 25], AD [n = 20], and non-AD dementia [n = 22]).
- Overall changes in management between pre- and post-PET occurred in 5.0% of CN, 52.0% of MCI, and 38.1% of dementia.
- Logistic regression analysis revealed that tau PET has stronger associations with change management than amyloid PET in all participants and dementia groups.
- Discussion The combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia, and the second-generation tau PET has a strong impact on the changes in diagnosis and management in memory clinics.
- Classification of evidence This study provides Class I evidence that the combination of amyloid and tau PETs was associated with changes in management and diagnosis of MCI and dementia.
Why it matters
In 126 memory clinic participants, combining amyloid and tau PET scans changed the suspected cause of symptoms in many patients and changed management for about half of those with mild cognitive impairment. Tau PET was more strongly linked to changes in management than amyloid PET.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants40
- Effect size84.9%; 25.0%; 68.0%
- Evidence strengthModerate
How this study scored 53/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 40 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 39 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.8 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 32 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Daisuke Ito: h-index 50 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Keio University: institution h-index 735 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36175151) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.